4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

Description

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment

Conditions

Neovascular (Wet) Age-Related Macular Degeneration

Talk to us

Study Overview

On this page

Study Details

Study overview

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment

A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults with Neovascular (Wet) Age-Related Macular Degeneration

4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

Condition
Neovascular (Wet) Age-Related Macular Degeneration
Intervention / Treatment

-

Contacts and Locations

Phoenix

Barnet Delaney Perkins Eye Center, Phoenix, Arizona, United States, 85016

Oxnard

California Retina Consultants, Oxnard, California, United States, 93036

Sacramento

Retinal Consultants Medical Group, Sacramento, California, United States, 95841

Lakewood

Colorado Retina Associates, Lakewood, Colorado, United States, 80288

Deerfield Beach

Rand Eye Institute, Deerfield Beach, Florida, United States, 33064

Gainesville

Vitreo Retinal Associates, Gainesville, Florida, United States, 32607

Melbourne

Florida Eye Associates, Melbourne, Florida, United States, 32901

Pensacola

Retinal Specialty Institute, Pensacola, Florida, United States, 32503

Tampa

Retina Vitreous Associates of Florida, Tampa, Florida, United States, 33607

Oak Forest

University Retina and Macula Associates, Oak Forest, Illinois, United States, 60452

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ≥50 years of age
  • * Diagnosed with macular CNV secondary to AMD
  • * BCVA ETDRS Snellen equivalent for dose escalation between \~20/32 and \~20/320, or for dose expansion and population extension between \~20/25 and\~20/200, for steroid optimization between \~20/25 and \~20/640
  • * Currently receiving anti-VEGF treatment in the study eye and has demonstrated a clinical response consistent with anti-VEGF activity within 12 months prior to screening
  • * Any condition preventing visual acuity improvement in the study eye
  • * Prior treatment with photodynamic therapy or retinal laser in the study eye
  • * History of uveitis in either eye
  • * Any other pre-existing eye conditions or surgical complications that would preclude participation in an interventional clinical trial or interfere with the interpretation of study endpoints

Ages Eligible for Study

50 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

4D Molecular Therapeutics,

Jennifer Lee, MD, STUDY_DIRECTOR, 4D Molecular Therapeutics

Study Record Dates

2026-11